Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics, Inc. announced the grant of 104,386 restricted stock units and stock options to newly hired employees, approved by its Compensation Committee under the 2018 Inducement Plan. The restricted stock units vest over four years, while the stock options provide a ten-year term with an exercise price of $17.50 per share, set to the closing price on the grant date of October 1, 2021. This move is compliant with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to building a skilled workforce.
Atara Biotherapeutics announced new data on ATA188 for progressive multiple sclerosis (MS), highlighting a two-year open-label extension (OLE) study. Significant findings include improved magnetization transfer ratio (MTR) indicative of possible remyelination and sustained disability improvement in patients over 33 months. Of 24 patients evaluated, 18 continued in the OLE, with 9 meeting sustained disability improvement criteria. The data presentation is scheduled for October 13, 2021, at the ECTRIMS Congress, showcasing Atara's commitment to developing innovative T-cell therapies for MS.
Atara Biotherapeutics (NASDAQ: ATRA) announced that the European Medicines Agency's CHMP granted accelerated assessment for its lead product candidate, tabelecleucel (tab-cel), aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Currently, there are no approved therapies for this life-threatening condition. The Marketing Authorization Application (MAA) is expected to be submitted in November 2021, with a potential approval decision anticipated in the second half of 2022.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 74,055 restricted stock units and stock options for 59,869 shares to newly hired employees. These awards, part of Atara's 2018 Inducement Plan, were approved by the Compensation Committee. The RSUs vest over four years, while the stock options have a ten-year term with an exercise price of $15.69 per share. This initiative aims to attract and retain talent in the competitive biotherapeutics market, adhering to Nasdaq rules.
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in a panel discussion at the Citi 16th Annual BioPharma Virtual Conference on September 9, 2021, at 7:40 a.m. PDT. The discussion will focus on the current landscape of cell therapy, including autologous and allogeneic CAR-T and CAR-NK therapies. Interested parties can access a live webcast through Atara's Investor Events and Presentations webpage, with an archived replay available for 30 days. Atara specializes in developing therapies for cancer and autoimmune diseases using its EBV T-cell platform.
Atara Biotherapeutics (ATRA) reported its Q2 2021 financial results, highlighting significant regulatory progress for tab-cel® and anticipated approvals in 2022. The company expects to submit a Biologics License Application for tab-cel® by Q1 2022 and aims for EU Marketing Authorization Application submission in November 2021. Financially, Atara recorded a net loss of $83.8 million, or $0.91 per share, with cash reserves at $373.4 million, projected to fund operations into 2023. Increased R&D expenses were noted, reflecting investments in pipeline programs.
Atara Biotherapeutics (Nasdaq: ATRA) announces the appointment of Ameet Mallik to its Board of Directors. Mr. Mallik, an expert in biotechnology with over 25 years of experience, has a successful history of bringing oncology therapeutics to market. His leadership is expected to enhance Atara's efforts to commercialize its lead product, tab-cel®, anticipated for approval in 2022. Mallik's expertise spans commercial operations at Novartis and Rafael Holdings, positioning him to drive Atara's mission of transforming the lives of patients with serious diseases.
Atara Biotherapeutics (Nasdaq:ATRA) announced the grant of 110,626 restricted stock units and stock options for 69,744 shares to newly hired employees. These awards were approved by the Compensation Committee under the 2018 Inducement Plan, effective August 2, 2021. The restricted stock units will vest over four years, with the first 25% vesting after one year. The stock options also vest over four years, starting with 25% after the first anniversary. This action complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics announced it will release its second quarter 2021 financial results post-market on August 9, 2021. Following the release, a live conference call will be held at 4:30 p.m. EDT to discuss financial results and provide corporate updates. Participants can join by calling 877-407-8291 for domestic callers or 201-689-8345 for international. The company aims to provide transformative therapies using its EBV T-cell platform to address serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has granted 124,580 restricted stock units and options to purchase 99,585 shares to newly hired employees as part of its 2018 Inducement Plan. The stock options have a ten-year term with an exercise price of $16.05 per share, aligning with the company's closing stock price on July 1, 2021. The awards support Atara’s strategy to attract talent in the competitive T-cell immunotherapy field, aimed at developing therapies for cancer and autoimmune diseases.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
